These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 21746944)
1. Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks. Krishna G; Ma L; Martinho M; Prasad P; Wahl J; Tavakkol A Antimicrob Agents Chemother; 2011 Sep; 55(9):4424-6. PubMed ID: 21746944 [TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Elewski B; Pollak R; Ashton S; Rich P; Schlessinger J; Tavakkol A Br J Dermatol; 2012 Feb; 166(2):389-98. PubMed ID: 21967490 [TBL] [Abstract][Full Text] [Related]
3. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Gupta AK; Leonardi C; Stoltz RR; Pierce PF; Conetta B; J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):437-43. PubMed ID: 15987289 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole. Pollak RA; Ilie C J Drugs Dermatol; 2017 Dec; 16(12):1269-1273. PubMed ID: 29240863 [TBL] [Abstract][Full Text] [Related]
5. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. De Doncker P; Decroix J; Piérard GE; Roelant D; Woestenborghs R; Jacqmin P; Odds F; Heremans A; Dockx P; Roseeuw D Arch Dermatol; 1996 Jan; 132(1):34-41. PubMed ID: 8546481 [TBL] [Abstract][Full Text] [Related]
6. Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis. Naeimifar A; Samadi A; Ahmad Nasrollahi S; Fattahi A; Ghasemi Z; Azizzadeh-Roodpishi S; Malakooti S; Ehsani AH; Firooz A; Dowlatiy Y Mycoses; 2020 May; 63(5):517-524. PubMed ID: 32048351 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Rich P; Scher RK; Breneman D; Savin RC; Feingold DS; Konnikov N; Shupack JL; Pinnell S; Levine N; Lowe NJ; Aly R; Odom RB; Greer DL; Morman MR; Bucko AD; Tschen EH; Elewski BE; Smith EB; Hilbert J J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S103-9. PubMed ID: 9631992 [TBL] [Abstract][Full Text] [Related]
8. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707 [TBL] [Abstract][Full Text] [Related]
9. Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients. Cook-Bolden FE; Lin T Cutis; 2017 Apr; 99(4):286-289. PubMed ID: 28492600 [TBL] [Abstract][Full Text] [Related]
10. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. Tschen EH; Bucko AD; Oizumi N; Kawabata H; Olin JT; Pillai R J Drugs Dermatol; 2013 Feb; 12(2):186-92. PubMed ID: 23377392 [TBL] [Abstract][Full Text] [Related]
11. Clinical Inquiry: which oral antifungal works best for toenail onychomycosis? Volk B; Tiu A; St Anna L J Fam Pract; 2013 Feb; 62(2):100-1. PubMed ID: 23405380 [TBL] [Abstract][Full Text] [Related]
12. Managing Assessments and Expectations: Patient Responses Following Therapy With Efinaconazole Topical Solution, 10%. Bhatia N J Drugs Dermatol; 2015 Jul; 14(7):694-8. PubMed ID: 26151785 [TBL] [Abstract][Full Text] [Related]
13. Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. Gupta AK; Cooper EA Skin Therapy Lett; 2021 Jan; 26(1):5-10. PubMed ID: 33539062 [TBL] [Abstract][Full Text] [Related]
15. Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis. Avner S; Nir N; Henri T J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1194-6. PubMed ID: 17062030 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10. Rosen T Cutis; 2015 Sep; 96(3):197-201. PubMed ID: 26562270 [TBL] [Abstract][Full Text] [Related]
17. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. Elewski BE; Rich P; Pollak R; Pariser DM; Watanabe S; Senda H; Ieda C; Smith K; Pillai R; Ramakrishna T; Olin JT J Am Acad Dermatol; 2013 Apr; 68(4):600-608. PubMed ID: 23177180 [TBL] [Abstract][Full Text] [Related]
18. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Sigurgeirsson B; van Rossem K; Malahias S; Raterink K J Am Acad Dermatol; 2013 Sep; 69(3):416-25. PubMed ID: 23706639 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. Watanabe S; Tsubouchi I; Okubo A J Dermatol; 2018 Oct; 45(10):1151-1159. PubMed ID: 30156314 [TBL] [Abstract][Full Text] [Related]
20. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail. Lipner SR; Scher RK Expert Rev Clin Pharmacol; 2015; 8(6):719-31. PubMed ID: 26325488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]